Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/28/2025 | $18.00 | Buy | H.C. Wainwright |
| 1/21/2025 | $17.00 | Buy | UBS |
| 3/14/2024 | $16.00 → $20.00 | Equal Weight → Overweight | Wells Fargo |
| 1/30/2024 | $22.00 | Outperform | Leerink Partners |
| 11/10/2023 | $11.00 | Overweight | Cantor Fitzgerald |
| 8/24/2023 | $5.00 → $6.00 | Underweight → Equal-Weight | Morgan Stanley |
| 2/22/2023 | $10.00 | Buy | Lake Street |
| 4/6/2022 | $13.00 | Outperform | Wolfe Research |
4 - NeuroPace Inc (0001528287) (Issuer)
4 - NeuroPace Inc (0001528287) (Issuer)
4 - NeuroPace Inc (0001528287) (Issuer)
NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2025 Healthcare Conference, on Wednesday, September 3 in Boston, MA. NeuroPace management will participate in a fireside chat discussion at the Cantor Global Healthcare Conference on Thursday, September 4 at 9:45am ET, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a live webcast here and a replay will be available on the
-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. Second Quarter
MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the following statement in response to the Centers for Medicare & Medicaid Services (CMS) electing not to finalize its proposed reassignment of epilepsy with neurostimulator cases in the FY 2026 Inpatient Prospective Payment System (IPPS) rule. "We appreciate CMS' openness to public comment on the proposed rule and its reconsideration of the original proposal to reassign RNS cases to MS-DRG 020-022. We commend CMS' decision to maintain the current MS-DRG assignment for RNS® System procedures un
SCHEDULE 13G/A - NeuroPace Inc (0001528287) (Subject)
10-Q - NeuroPace Inc (0001528287) (Filer)
8-K - NeuroPace Inc (0001528287) (Filer)
H.C. Wainwright initiated coverage of NeuroPace with a rating of Buy and set a new price target of $18.00
UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00
Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously
Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role MOUNTAIN VIEW, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Patrick F. Williams as Chief Financial Officer, effective June 20, 2025. Ms. Rebecca Kuhn has entered into an agreement with the Company to depart from her CFO role and serve in an advisory role to the Company for a twelve-month period. "NeuroPace is pleased to have a finan
MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments
Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma
-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAIN VIEW, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. Second Quarter
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of 2025 after market close on Tuesday, August 12, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). Investors interested in listening to the conference call may do so by accessing a live webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1724652&tp_key=858d589533. Individuals interested in participating in the call via telephone may acces
-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming favorable safety profile of the RNS® System -- Primary effectiveness endpoint did not reach statistical significance in overall study population but showed a statistically significant response in a subset, which represents the majority of participants -- Preliminary data illustrates the overall value of the RNS System to individualize patient treatment over time, showing mor
SC 13G/A - NeuroPace Inc (0001528287) (Subject)
SC 13G/A - NeuroPace Inc (0001528287) (Subject)
SC 13G/A - NeuroPace Inc (0001528287) (Subject)